Volume 21 Issue 2
Feb.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(2): 217-220
LIU Kai, SU Yan, QU Hong-dang, DU Yuan-yuan, XIONG Bo-chao, XU Li, LUO Song. Study of serum cystatin C levels in patients with vascular cognitive impairment[J]. Chinese Journal of General Practice, 2023, 21(2): 217-220. doi: 10.16766/j.cnki.issn.1674-4152.002849
Citation: LIU Kai, SU Yan, QU Hong-dang, DU Yuan-yuan, XIONG Bo-chao, XU Li, LUO Song. Study of serum cystatin C levels in patients with vascular cognitive impairment[J]. Chinese Journal of General Practice, 2023, 21(2): 217-220. doi: 10.16766/j.cnki.issn.1674-4152.002849
shu

Study of serum cystatin C levels in patients with vascular cognitive impairment

doi: 10.16766/j.cnki.issn.1674-4152.002849

  • Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0364

 20190629

  • Received Date: 2022-05-05
    Available Online: 2023-04-20
    Abstract
  •   Objective  To determine the expression of serum cystatin C (CysC) in patients with vascular cognitive impairment (VCI), and to explore the correlation between them and the clinical predictive value of CysC.  Methods  This study included 96 patients with VCI who were enrolled in the First Affiliated Hospital of Bengbu Medical College from January 2021 to February 2022. They were divided into vascular dementia group (VaD, n=35) and vascular cognitive impairment without dementia group (VCIND, n=61) according to the Montreal Cognitive Assessment (MoCA) and ability of daily living (ADL) scores. In addition, 83 healthy elderly with normal cognitive function and brain MRI/CT were selected as normal controls (NC group). Baseline data and serum CysC levels were compared to analyse the relationship of CysC with overall cognition and its specific cognitive domains in patients with VCI. Binary logistic regression and ROC curves were used to evaluate VCI-related risk factors and the predictive value of CysC for the occurrence of VCI.  Results  Significant differences in age, history of hypertension, diabetes, stroke, MoCA scores and CysC were found among the three groups (all P < 0.05). The serum CysC expression increased sequentially in the NC, VCIND and VaD groups, and the differences were statistically significant (all P < 0.05). CysC was negatively correlated with MoCA overall cognition, visual space and executive function, naming, attention and computation, language, delayed memory and orientation in the VCI group (all P < 0.05). The results of multivariate logistic regression model indicated that higher levels of CysC were independent risk factors for VCI (P < 0.05). ROC curve analysis showed that the area under curve (AUC) for predicting the occurrence of VCI by serum CysC level was 0.758, the sensitivity was 70.8%, the specificity was 77.1% and the optimal cut-off value was 0.99 mg/L.  Conclusion  Serum CysC is highly expressed in VCI and is related to the severity of cognitive impairment. It is an independent influencing factor of cognitive impairment and is expected to become a biological indicator for early assessment of VCI.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    DICHGANS M, LEYS D. Vascular cognitive impairment[J]. Circ Res, 2017, 120(3): 573-591. doi: 10.1161/CIRCRESAHA.116.308426
    [2]
    LIVINGSTON G, HUNTLEY J, SOMMERLAD A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission[J]. Lancet, 2020, 396(10248): 413-446. doi: 10.1016/S0140-6736(20)30367-6
    [3]
    LEES J S, WELSH C E, CELIS-MORALES C A, et al. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease[J]. Nat Med, 2019, 25(11): 1753-1760. doi: 10.1038/s41591-019-0627-8
    [4]
    ROTHENBACHER D, REHM M, IACOVIELLO L, et al. Contribution of cystatin C and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project[J]. BMC Med, 2020, 18(1): 300. doi: 10.1186/s12916-020-01776-7
    [5]
    VIGGIANO D, WAGNER C A, MARTINO G, et al. Mechanisms of cognitive dysfunction in CKD[J]. Nat Rev Nephrol, 2020, 16(8): 452-469. VIGGIANO D, WAGNER C A, MARTINO G, et al. Mechanisms of cognitive dysfunction in CKD[J]. Nat Rev Nephrol, 2020, 16(8): 452-469. doi: 10.1038/s41581-020-0266-9
    [6]
    CUI Z Z, CAO G Z, WANG Y Y, et al. Effects of cystatin C on cognitive impairment in older Chinese adults[J]. Am J Alzheimers Dis Other Demen, 2020, 35: 1533317520965101. DOI: 10.1177/1533317520965101.
    [7]
    CHEN X P, HUANG Y, BAO T, et al. Changes in serum cystatin C levels and the associations with cognitive function in Alzheimer's disease patients[J]. Front Aging Neurosci, 2022, 13: 790939. DOI: 10.3389/fnagi.2021.790939.
    [8]
    GHIDONI R, BENUSSI L, GLIONNA M, et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment[J]. J Alzheimers Dis, 2010, 22(3): 985-991. doi: 10.3233/JAD-2010-101095
    [9]
    中国医师协会神经内科分会认知障碍专业委员会, 《中国血管性认知障碍诊治指南》编写组. 2019年中国血管性认知障碍诊治指南[J]. 中华医学杂志, 2019, 99(35): 2737-2744. doi: 10.3760/cma.j.issn.0376-2491.2019.35.005

    Cognitive Disorders Professional Committee, Neurology Branch, Chinese Medical Doctor Association, Writing group of Chinese Guidelines for the diagnosis and treatment of vascular cognitive Impairment. Guidelines for Diagnosis and Treatment of vascular cognitive Impairment in China, 2019[J]. 中华医学杂志, 2019, 99(35): 2737-2744. doi: 10.3760/cma.j.issn.0376-2491.2019.35.005
    [10]
    甘露, 刘涛, 王淑华, 等. 中文版简明精神状态量表与蒙特利尔认知评估量表临床应用进展[J]. 中国康复医学杂志, 2017, 32(7): 842-845. doi: 10.3969/j.issn.1001-1242.2017.07.026

    GAN L, LIU T, WANG S H, et al. Clinical application of the Chinese version of the concise mental state scale and the montreal cognitive assessment scale[J]. Chinese Journal of Rehabilitation Medicine, 2017, 32(7): 842-845. doi: 10.3969/j.issn.1001-1242.2017.07.026
    [11]
    BOLAND J R. DSM-5 (R) guidebook: the essential companion to the diagnostic and statistical manual of mental disorders, 5th edition[J]. J Psychiatr Pract, 2015, 21(2): 171-173. doi: 10.1097/01.pra.0000462610.04264.fa
    [12]
    ZENG Q, HUANG Z H, WEI L L, et al. Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction[J]. Neurol Sci, 2019, 40(5): 1049-1054. doi: 10.1007/s10072-019-03777-8
    [13]
    叶明, 陈育华, 刘晓林, 等. 帕金森病患者血清半胱氨酸蛋白酶抑制剂C水平的变化及其临床意义[J]. 中华全科医学, 2016, 14(12): 2004-2007. doi: 10.16766/j.cnki.issn.1674-4152.2016.12.010

    YE M, CHEN Y H, LIU X L, et al. The clinical significance of serum cystatin C level change in Parkinson's disease[J]. Chinese Journal of General Practice, 2016, 14(12): 2004-2007. doi: 10.16766/j.cnki.issn.1674-4152.2016.12.010
    [14]
    YAO T T, SONG G P, LI Y H, et al. Chronic kidney disease correlates with MRI findings of cerebral small vessel disease[J]. Ren Fail, 2021, 43(1): 255-263. doi: 10.1080/0886022X.2021.1873804
    [15]
    DUAN J H, MARCELLUS K A, QIN X K, et al. Cystatin C promotes tau protein phosphorylation and causes microtubule instability by inhibiting intracellular turnover of GSK3β in neurons[J]. Mol Cell Neurosci, 2018, 89: 1-8. doi: 10.1016/j.mcn.2018.03.009
    [16]
    PERLENFEIN T J, MURPHY R M. A mechanistic model to predict effects of cathepsin B and cystatin C on β-amyloid aggregation and degradation[J]. J Biol Chem, 2017, 292(51): 21071-21082. doi: 10.1074/jbc.M117.811448
    [17]
    SHEIKH A M, WADA Y, TABASSUM S, et al. Aggregation of cystatin C changes its inhibitory functions on protease activities and amyloid β fibril formation[J]. Int J Mol Sci, 2021, 22(18): 9682. doi: 10.3390/ijms22189682
    [18]
    FANG Z P, FENG Y, LI Y H, et al. Neuroprotective autophagic flux induced by hyperbaric oxygen preconditioning is mediated by cystatin C[J]. Neurosci Bull, 2019, 35(2): 336-346. doi: 10.1007/s12264-018-0313-8
    [19]
    WU H X, DU Q N, DAI Q Y, et al. Cysteine protease cathepsins in atherosclerotic cardiovascular diseases[J]. J Atheroscler Thromb, 2018, 25(2): 111-123. doi: 10.5551/jat.RV17016
    [20]
    ZHANG Y R, SUN L. Cystatin C in cerebrovascular disorders[J]. Curr Neurovasc Res, 2017, 14(4): 406-414.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (215) PDF downloads(8) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return